Pricing Log in Create free account

Aprea Therapeutics, Inc. (APRE) vs XTL Biopharmaceuticals Ltd. (XTLB)

Aprea Therapeutics, Inc. and XTL Biopharmaceuticals Ltd. are both Biotechnology companies. Aprea Therapeutics, Inc. and XTL Biopharmaceuticals Ltd. are of similar size ($8.1M and $7.8M). XTL Biopharmaceuticals Ltd. grew revenue faster over the last twelve months: −12.7% against −81.0%. Across the 12 metrics below, XTL Biopharmaceuticals Ltd. leads on 7 and Aprea Therapeutics, Inc. on 5.

Valuation

Metric APRE XTLB Biotechnology median
P/E n/m n/m 8.50
P/S 108.58 1.36 9.71
P/B 0.81 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.77 n/m 0.64
EV/Sales (35.75) 1.27 9.21
Earnings yield (186.21%) (14.29%) (33.15%)
Free cash flow yield (39.30%) (139.25%) (25.50%)

Profitability

Metric APRE XTLB Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (47.44%) 0.00% (56.36%)
Return on assets (41.30%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric APRE XTLB Biotechnology median
Revenue growth (TTM) (80.99%) (12.71%) 6.02%
EPS growth (last fiscal year) 17.87% (159.17%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric APRE XTLB Biotechnology median
Debt to equity 0.00 (1.83) 0.00
Current ratio 13.55 0.70 4.72
Net debt to EBITDA 1.11 (0.11) 0.96

Dividend

Metric APRE XTLB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric APRE XTLB Biotechnology median
Market cap 7.78m 8.10m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack